Log in

CVE:ADK - Diagnos Stock Price, Forecast & News

-0.01 (-3.85 %)
(As of 02/23/2020 04:00 PM ET)
Today's Range
Now: C$0.25
50-Day Range
MA: C$0.22
52-Week Range
Now: C$0.25
Volume143,500 shs
Average Volume49,974 shs
Market CapitalizationC$12.37 million
P/E RatioN/A
Dividend YieldN/A
DIAGNOS Inc. provides software-based interpretation services primarily in Canada, the United Arab Emirates, Saudi Arabia, Slovakia, and the United States. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. DIAGNOS Inc. has a collaboration agreement with ÉTS, École de technologie supérieure. The company was founded in 1998 and is headquartered in Brossard, Canada.

Industry, Sector and Symbol

Industry Health Information Services
SectorComputer and Technology



Sales & Book Value

Annual SalesC$349,149.00
Cash FlowC$0.01 per share
Book ValueC$0.00 per share



Market CapC$12.37 million
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable

Receive ADK News and Ratings via Email

Sign-up to receive the latest news and ratings for ADK and its competitors with MarketBeat's FREE daily newsletter.

Diagnos (CVE:ADK) Frequently Asked Questions

What is Diagnos' stock symbol?

Diagnos trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ADK."

How were Diagnos' earnings last quarter?

Diagnos Inc (CVE:ADK) issued its quarterly earnings results on Wednesday, November, 27th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $0.08 million for the quarter. View Diagnos' Earnings History.

When is Diagnos' next earnings date?

Diagnos is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Diagnos.

Has Diagnos been receiving favorable news coverage?

Headlines about ADK stock have trended somewhat negative on Sunday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Diagnos earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Diagnos.

Who are some of Diagnos' key competitors?

What other stocks do shareholders of Diagnos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diagnos investors own include Marijuana Company Of America (MCOA), Maxar Technologies (MAXR) and Main Street Capital (MAIN).

Who are Diagnos' key executives?

Diagnos' management team includes the folowing people:
  • Mr. André Larente, CEO, Pres & Exec. Director
  • Mr. Marc-André Massue, VP of Fin., CFO & Sec.
  • Mr. Guillermo Moreno Robles, VP of Sales
  • Dr. Hadi Chakor Djelthia, Chief Medical Officer

How do I buy shares of Diagnos?

Shares of ADK and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Diagnos' stock price today?

One share of ADK stock can currently be purchased for approximately C$0.25.

How big of a company is Diagnos?

Diagnos has a market capitalization of C$12.37 million and generates C$349,149.00 in revenue each year. View Additional Information About Diagnos.

What is Diagnos' official website?

The official website for Diagnos is http://www.diagnos.ca/.

How can I contact Diagnos?

Diagnos' mailing address is 7005 Taschereau Blvd, Suite 340 Brossard, BROSSARD, QC J4Z 1A7, Canada. The company can be reached via phone at +1-450-6788882.

MarketBeat Community Rating for Diagnos (CVE ADK)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Diagnos and other stocks. Vote "Outperform" if you believe ADK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel